CDEK
← All drugs Report issue

desflurane

Trade name: suprane

Small moleculeapproved

Approved

Sep 18, 1992

Desflurane is a non-flammable liquid administered via vaporizer as a general anesthetic. It is halogenated exclusively with fluorine and is very resistant to defluorination. For this reason, it is not associated with nephrotoxicity, as is the case with other inhalational anesthetics. Desflurane is indicated for the induction and/or maintenance of anesthesia and adults, and for maintenance of anesthesia in pediatric patients following the induction with other agents. — NCATS

Clinical trial activity

221 trials · 178 clinical orgs · 3 marketing orgs

Phase 1
29
Phase 2
46
Phase 3
19
Phase 4
57

Earliest trial started Aug 1, 1999 (NCT00125502)

Timeline

1990s

  1. Sep 18, 1992

    Baxter — Earliest FDA Approval

  2. Sep 18, 1992

    Baxter — NDA Organization

  3. Sep 18, 1992

    Baxalta — NDA Secondary Org

  4. Jan 1, 1999

    Earliest Phase 1 Sponsor(trial)

  5. Jan 1, 1999

    Earliest Phase 2 Sponsor(trial)

2000s

  1. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Feb 26, 2018

    Hengrui Therapeutics, Inc. — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedSep 18, 1992

Chemistry & pharmacology

Loading structure…

SMILES

FC(F)OC(F)C(F)(F)F
Mol. weight
168.0378 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Prescription Only

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane
  • 1,1,1,2-tetrafluoro-2-(difluoromethoxy)ethane
  • (+-)-2-difluoromethyl 1,2,2,2-tetrafluoroethyl ether
  • (+-)-2-difluoromethyl 1,2,2,2-tetrafluoroethyl ether
  • (all-e)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene
  • (all-e)-2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene
  • baxter anaesthesia brand of desflurane
  • baxter brand of desflurane
  • desflurane
  • desflurane
  • desflurane
  • desflurane
  • desflurane
  • desflurane
  • desflurane
  • desflurane
  • desflurane
  • desflurano
  • desflurano
  • desfluranum
  • desfluranum
  • difluoromethyl 1,2,2,2-tetrafluoroethyl ether
  • difluoromethyl 1,2,2,2-tetrafluoroethyl ether
  • difluoromethyl 1,2,2,2-tetrafluoroethyl ether
  • difluoromethyl 1,2,2,2-tetrafluoroethyl ether
  • difluoromethyl 1,2,2,2-tetrafluoroethyl ether
  • ethane, 2-(difluoromethoxy)-1,1,1,2-tetrafluoro-
  • i653
  • i 653
  • i-653
  • i-653
  • i-653
  • mf59
  • mf59
  • mf59
  • mf-59
  • mf59 oil emulsion
  • ohmeda brand of desflurane
  • spinacene
  • spinacene
  • squalene
  • squalene
  • squalene
  • supraene
  • supraene
  • supraene
  • suprane
  • suprane
  • suprane
  • suprane
  • zeneca brand of desflurane

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07295158N/AJan 1, 2026Konya City Hospital
NCT07239479N/ADec 1, 2025Tam Anh Research Institute
NCT07271472N/ADec 1, 2025Ataturk University
NCT07116733Phase 3Oct 20, 2025Xijing Hospital
NCT07123870Phase 4Jul 23, 2025Kocaeli City Hospital
NCT07016308N/AJun 10, 2025Harran University
NCT07304479N/AMay 1, 2025University of Athens
NCT06779890Phase 4Mar 1, 2025Aristotle University of Thessaloniki
NCT06772558N/AFeb 1, 2025Inner Mongolia Baogang Hospital
NCT06252207N/AJan 15, 2025The Cleveland Clinic
NCT06457958Phase 4Nov 1, 2024Kocaeli City Hospital, The Scientific and Technological Research Council of Turkey
NCT07289945Phase 3Sep 15, 2024Rouen Normandy University
NCT06387836N/AApr 23, 2024Fudan University
NCT06241131Early Phase 1 (Phase 1)Mar 1, 2024Sichuan University
NCT06123624N/ANov 27, 2023Ajou University
NCT06207344N/AOct 21, 2023Chongqing Medical University
NCT06176144N/ASep 10, 2023Sichuan University
NCT05990790Phase 4Sep 3, 2023Medical University of Vienna
NCT05866315N/AMay 19, 2023Wonkwang University
NCT05783518Phase 4Mar 27, 2023Tianjin Medical University
Showing 20 of 221 trials
Page 1 / 12

Organizations

Research & Development (178)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Allergy and Infectious Diseases (NIAID)Government222131999
NovartisFor profit211742006
Yonsei UniversityAcademic/Hospital151522010
BaxaltaFor profit11132007
Seoul National UniversityAcademic/Hospital111122012
Kangbuk Samsung HospitalAcademic/Hospital6622015
Capital Medical UniversityAcademic/Hospital4422021
Postgraduate Institute of Medical Education and ResearchAcademic/Hospital4222015
GlaxoSmithKlineFor profit3132014
Ohio State UniversityAcademic/Hospital3322010
Sanofi-AventisFor profit3011999
Ajou UniversityAcademic/Hospital2222014
Aristotle University of ThessalonikiAcademic/Hospital2222016
Bill and Melinda Gates FoundationAcademic/Hospital2022015
Cairo UniversityAcademic/Hospital2212014
Cantonal Hospital of St. GallenAcademic/Hospital2012011
Catholic University of KoreaAcademic/Hospital2222011
Chosun UniversityAcademic/Hospital2212013
Chung-Ang UniversityAcademic/Hospital2212013
Department of Health and Human ServicesGovernment2212016
178 organizations
Page 1 / 9

Marketing (3)

OrganizationOrg typeRelationshipDate
BaxaltaFor profitNDA2Sep 18, 1992
BaxterFor profitNDASep 18, 1992
Hengrui Therapeutics, Inc.For profitMKTGFeb 26, 2018